Research programme: synthetic biology therapeutics - Synlogic

Drug Profile

Research programme: synthetic biology therapeutics - Synlogic

Alternative Names: SYNB1020; Synthetic biotics - Synlogic

Latest Information Update: 02 Sep 2016

Price : $50

At a glance

  • Originator Synlogic
  • Developer AbbVie; Synlogic
  • Class Gene therapies
  • Mechanism of Action Metagenome modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Inborn urea cycle disorders
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Inborn urea cycle disorders; Phenylketonuria
  • Research Inflammatory bowel diseases

Most Recent Events

  • 29 Aug 2016 Research programme: synthetic biology therapeutics - Synlogic receives Orphan Drug status for Inborn urea cycle disorders in USA
  • 29 Aug 2016 Preclinical trials in Phenylketonuria in USA (PO)
  • 29 Aug 2016 Preclinical trials in Inborn urea cycle disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top